DDX41胚系突变在接受强化治疗的急性髓系白血病患者中的预后影响:一项ALFA-FILO研究
该研究描述了191例DDX41胚系突变(DDX41MutGL)急性髓系白血病(AML)患者的临床和生物学特征,并将其中86例接受强化化疗的患者与1604例DDX41野生型(DDX41WT)AML患者进行比较,DDX41MutGL患病率为5%。DDX41MutGL患者完全缓解率更高(94% vs 69%;P < .0001),截至造血干细胞移植(HSCT)的限制性平均总生存更长,但3年时复发率与中危/高危DDX41WT患者相似。首次完全缓解期接受HSCT与延长无复发生存相关(HR 0.43;95%CI 0.21-0.88;P = .02),但与总生存延长无关。
要点
- DDX41MutGL AML患者以男性为主(75%),中位年龄第七个十年,白细胞计数中位数2×10^9/L,骨髓原始细胞中位数33%。
- DDX41MutGL患者完全缓解率94% vs DDX41WT 69%(P < .0001),5年限制性平均生存时间差异13.6个月(P < .001)。
- 首次完全缓解期HSCT与延长无复发生存相关(HR 0.43;95%CI 0.21-0.88;P = .02),但与总生存无关(HR 0.77;95%CI 0.35-1.68;P = .5)。
核心结论
- DDX41MutGL AML具有独特的临床和生物学特征,完全缓解率高且早期复发率低,但后期复发率与中危/高危DDX41WT相似。
- 首次完全缓解期HSCT与延长无复发生存相关,但与总生存延长无关。
研究设计与样本
- 研究纳入191例DDX41MutGL AML患者,其中86例接受强化化疗并来自5项前瞻性ALFA/FILO临床试验,与1604例DDX41WT AML患者进行比较。
主要发现
- DDX41MutGL AML患病率为5%,患者多为男性(75%),中位年龄第七个十年,白细胞计数中位数2×10^9/L,骨髓原始细胞中位数33%,正常核型75%,附加体细胞突变中位数2个。
- 82%的DDX41MutGL患者发现第二个体细胞DDX41突变(DDX41MutSom),克隆架构推断提示其可能是AML进展的主要驱动因素。
- DDX41MutGL患者完全缓解率94% vs DDX41WT 69%(P < .0001),截至HSCT的限制性平均总生存较2017 ELN中危/高危DDX41WT患者更长(5年限制性平均生存时间差异13.6个月;P < .001)。
- 截至HSCT的复发率在1年时DDX41MutGL患者较低(15% vs 44%),但3年时增至与中危/高危DDX41WT患者相似(82% vs 75%)。
- 首次完全缓解期HSCT与延长无复发生存相关(HR 0.43;95%CI 0.21-0.88;P = .02),但与总生存延长无关(HR 0.77;95%CI 0.35-1.68;P = .5)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DDX41 germline mutations (DDX41MutGL) are the most common genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that DDX41MutGL myeloid malignancies could be considered as a distinct entity, even if their specific presentation and outcome remain to be defined. We describe here the clinical and biological features of 191 patients with DDX41MutGL AML. Baseline characteristics and outcome of 86 of these patients, treated with intensive chemotherapy in 5 prospective Acute Leukemia French Association/French Innovative Leukemia Organization trials, were compared with those of 1604 patients with DDX41 wild-type (DDX41WT) AML, representing a prevalence of 5%. Patients with DDX41MutGL AML were mostly male (75%), in their seventh decade, and with low leukocyte count (median, 2 × 109/L), low bone marrow blast infiltration (median, 33%), normal cytogenetics (75%), and few additional somatic mutations (median, 2). A second somatic DDX41 mutation (DDX41MutSom) was found in 82% of patients, and clonal architecture inference suggested that it could be the main driver for AML progression. DDX41MutGL patients displayed higher complete remission rates (94% vs 69%; P < .0001) and longer restricted mean overall survival censored at hematopoietic stem cell transplantation (HSCT) than 2017 European LeukemiaNet intermediate/adverse (Int/Adv) DDX41WT patients (5-year difference in restricted mean survival times, 13.6 months; P < .001). Relapse rates censored at HSCT were lower at 1 year in DDX41MutGL patients (15% vs 44%) but later increased to be similar to Int/Adv DDX41WT patients at 3 years (82% vs 75%). HSCT in first complete remission was associated with prolonged relapse-free survival (hazard ratio, 0.43; 95% confidence interval, 0.21-0.88; P = .02) but not with longer overall survival (hazard ratio, 0.77; 95% confidence interval, 0.35-1.68; P = .5).
引用
- Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022. PMID: 35443031. doi:10.1182/blood.2021015328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。